#Recovery rate of COVID infected patients

[pandemic-info]

What Is Long COVID? Understanding the Pandemic’s Mysterious Fallout > News > Yale Medicine

Originally published: April 15, 2024. Updated: June 4, 2024

Just weeks after the first cases of COVID-19 hit U.S. shores, an op-ed appeared in The New York Times titled “We Need to Talk About What Coronavirus Recoveries Look Like: They're a lot more complicated than most people realize.”

...

Unlike most diseases, Long COVID was first described not by doctors, but by the patients themselves. Even the term “Long COVID” was coined by a patient. Dr. Elisa Perego, an honorary research fellow at University College in London, came up with the hashtag #LongCOVID when tweeting about her own experience with the post-COVID syndrome. The term went viral and suddenly social media, and then the media itself, was full of these stories.

Complaints like "I can't seem to concentrate anymore" or "I'm constantly fatigued throughout the day" became increasingly common, seemingly appearing out of nowhere. With nothing abnormal turning up from their many thorough lab tests, patients and their physicians were left feeling helpless and frustrated.

The World Health Organization (WHO) has defined Long COVID as the "continuation or development of new symptoms three months after the initial SARS-CoV-2 infection, with these symptoms lasting for at least two months with no other explanation." This deliberately broad definition reflects the complex nature of this syndrome. We now understand that these symptoms are wide-ranging, including heart palpitations, cough, nausea, fatigue, cognitive impairment (commonly referred to as "brain fog"), and more. Also, many who experience Long COVID following an acute infection face an elevated risk of such medical complications as blood clots and (type 2) diabetes.

In April 2024, an estimated 5.3% of all adults in the United States reported having Long COVID, according to the Centers for Disease Control and Prevention (CDC). Data from the CDC suggest that Long COVID disproportionately affects women, and individuals between the ages of 40 and 59 have the highest reported rates of developing this post-acute infection syndrome.

...

Inderjit Singh, MBChB, a YSM assistant professor specializing in pulmonary, critical care, and sleep medicine, and director of the Pulmonary Vascular Program, is actively engaged in clinical trials aimed at uncovering the fundamental underpinnings of Long COVID.

...

Through this work, a significant revelation emerged. They observed that patients grappling with Long COVID and facing exercise difficulties were unable to efficiently extract oxygen from their bloodstream during physical exertion. This discovery identifies a specific cause underlying the biological underpinnings of Long COVID.

... Dr. Singh, along with other researchers, is focused on the identification of blood-based markers to assess the severity of Long COVID. For example, a research group, led by Akiko Iwasaki, PhD, Sterling Professor of Immunobiology and Molecular, Cellular, and Developmental Biology, and director of the Center for Infection & Immunity at YSM, most recently created a new method to classify Long COVID severity with circulating immune markers.

Further investigations conducted by Dr. Singh's team identified distinctive protein signatures in the blood of Long COVID patients, which correlated with the degree of Long COVID severity. Researchers identified two major and distinct blood profiles among the patients. Some of them exhibited blood profiles indicating that excessive inflammation played a prominent role in their condition, while others displayed profiles indicative of impaired metabolism.

...

Researchers currently believe that the impairment of a spectrum of key bodily functions may contribute to these diverse symptoms. These potential mechanisms include compromised immune system function, damage to blood vessels, and direct harm to the brain and nervous system. Importantly, it's likely that most patients experience symptoms arising from multiple underlying causes, which complicates both the diagnosis and treatment of Long COVID.

...

The last word from Lisa Sanders, MD:

I’m the internist who sees patients at Yale New Haven Health’s Multidisciplinary Long COVID Care Center. In our clinic, patients are examined by a variety of specialists to determine the best next steps for these complex patients. Sometimes that entails more testing. Often patients have had extensive testing even before they arrive, and far too often—when all the tests are normal—both doctors and patients worry that their symptoms are “all in their head.”

One of our first tasks is to reassure patients that many parts of Long COVID don’t show up on tests. We don’t know enough about the cause of many of these symptoms to create a test for them. The problem is not with the patient with the symptoms, but of the science surrounding them. If any good can be said to come out of this pandemic, it will be a better understanding of Long COVID and many of the other post-acute infection syndromes that have existed as long as the infections themselves.

[covid-safer-hotties]

Also preserved in our archive

The cost is set to go far beyond human suffering, yet almost five years into the pandemic, not only are there still no treatments for long Covid, there aren’t even any diagnostic tools – and we don’t seem overly interested in finding them.

The jig is up. People are catching on that “mild” Covid-19 may not be so mild, and that the mysterious lingering symptoms they’ve experienced after catching the virus, such as fatigue and brain fog, may just be connected. For others, this will be the first time that they put two and two together. I hate to be the bearer of bad news, but strap in for what comes next.

Recently, RNZ ran a piece outlining the estimated $2bn per year economic cost of long Covid in New Zealand and signalling that further research would be needed to determine a more precise figure. The average reader would assume that this research is under way or has at least been planned and funded. Human suffering aside, such a hit to productivity would surely raise alarm bells across the political spectrum!

I say this solemnly: yeah… nah.

Almost five years into the pandemic, not only are there still no treatments for long Covid, there also aren’t even any diagnostic tools – and we don’t seem overly interested in finding them.

At present, a long Covid diagnosis relies on a patient finding a doctor with up-to-date knowledge, who will believe their symptoms, and who will spend time investigating further to rule out other possibilities. This mythical trifecta is out of reach for most people, particularly women, who are affected by immune conditions at far higher rates, but have their symptoms written off as hysteria; and Māori and Pasifika, who face barriers to healthcare, and have their symptoms written off as laziness. Obtaining accurate data on prevalence under these circumstances is simply impossible.

In this way, and several others, long Covid mirrors ME/CFS (myalgic encephalomyelitis), a brutally debilitating biophysical condition, though the oft misused term “chronic fatigue” doesn’t quite convey that. Around half of long Covid sufferers meet the criteria for ME/CFS, which by the World Health Organization’s scale has a worse disease burden than HIV/Aids, multiple sclerosis (MS), and many forms of cancer. But again, there are no treatments.

I suffer from ME/CFS myself. My illness predates Covid-19 and came on after an infection with cytomegalovirus (CMV). I went from a fit and active young man to debilitatingly sick and fatigued, with several unexplained symptoms.

Pre-pandemic there was estimated to be more than 25,000 people in New Zealand suffering from ME/CFS, and only one specialist in the country, working one day a week, who has since retired (well earned, bless her). For years I had been praying for any sort of diagnosis, even if it was bad, so that I could get on the path to recovery. I got the diagnosis – but for a disease with no path to recovery.

As the pandemic unfolded, patients and advocates in the ME/CFS community warned that a tsunami of disability was approaching. They were of course ignored, as they have been for decades, and are now joined by masses of long Covid sufferers facing the reality that the medical profession has no answers for them, except perhaps euthanasia.

Frustrated with my lack of options, I connected with cellular immunologist Dr Anna Brooks, who had become a leading expert on long Covid, so I assumed that her biomedical research would be well supported. Alas, she detailed the uphill grind that it’s been to gain traction compared to other countries, and that generous donations, usually from patients themselves, had been the driving force of funding.

Together we founded DysImmune Research Aotearoa, with the goal of developing diagnostic tools leading to treatment for post-viral illnesses like long Covid and ME/CFS. In layman’s terms, we collect blood samples, analyse differences in cells, and put together an immune profile. My priority is ensuring that Māori and Pasifika patients and researchers are at the table and taking action into our own hands.

We’ve made a small start, and we have some incredible collaborations lined up, with far-reaching implications for community health. We’re in the process of seeking partnerships to take things forward. The expertise exists, it’s here in New Zealand. Still, the barrier to progress across the research space is the urgency for resourcing. It is dire to say the least.

Without some long-term project certainty, it’s difficult to pull the necessary teams together. While study after study illuminates more horrifying long-term effects of Covid infections, and prevention has been completely abandoned, research and development for treatments for long Covid is tanking. The private sector is at the whim of the quarterly financial report, and with no guaranteed short-term profit in treating us, it has very little incentive to take the risk.

So, barring some philanthropic miracle, only government can fill this gap. Yet where Australia had set aside A$50m specifically for long Covid research, and the US Senate considers a billion-dollar long Covid “moonshot” bill, New Zealand has allocated nothing. We’re fast asleep at the wheel. No other country can determine how many of our people are impacted by post-viral illnesses. No other country can address our specific needs.

Since this government is focused on ambition, productivity and fast-tracking, I assume they’d want to be world leaders in research, warp-speed some projects, and get long Covid sufferers back into work, no? This is what we are calling for. Not surveys. Not “talk” therapy and positive thinking. Biomedical research.

Put the money down and commit to this. Seize this opportunity to right decades of neglect. There are tens of thousands of us fighting for our lives, and millions more around the world. You think it won’t be you, then after your next inevitable Covid-19 reinfection, it is, and you’re left to wonder why nobody stepped up.

Government, iwi and whānau ora groups, health organisations, philanthropists – reach out. Let’s work.

Rohan Botica (Te Ātihaunui-a-Pāpārangi, Ngāti Tūwharetoa) is a lived-experience researcher and co-founder of DysImmune Research Aotearoa.

[flutterbyfairy]

i've been collecting resources and studies about myalgic encephalomyelitis for upcoming doctors appointments, and since there's a lot of misinformation about ME out there i thought i'd make a post with links and information that might be helpful for other ME patients, or just generally educational!

for anyone who doesn't know, myalgic encephalomyelitis is a debilitating multi system chronic illness. it's most characteristic symptom is post exertional malaise/symptom exacerbation (meaning symptoms getting significantly worse after exertion with prolonged recovery periods - see the diagnostic criteria linked below for more explanation). it has previously been called chronic fatigue syndrome, a name associated with claims of it being a psychosomatic condition rather than a medical one despite evidence to the contrary (here's a page with some information about the history of ME, and see the pathology section further down for evidence of ME being a physical disease). ME is also often comorbid with conditions like POTS (or other forms of orthostatic intolerance and dysautonomia), MCAS, and Small Fibre Neuropathy, and it's not uncommon for people who have long covid to develop ME. but yea! here's some links to resources i've gathered.

general resources/overviews:

Chronic Fatigue Syndrome Myalgic Encephalomyelitis Primer For Clinical Practitioners 2014 Edition

Diagnosis and Management of Myalgic Encephalomyelitis - ME Action

Initiating Care of a Patient With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)

Medical considerations when treating urgently ill patients with underlying myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)

Caring for the Patient with Severe or Very Severe Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

Three Cases of Severe ME/CFS in Adults

diagnostics:

Myalgic Encephalomyelitis: International Consensus Criteria <- just the criteria

Myalgic encephalomyelitis: International Consensus Criteria <- criteria with explanation of how and why it was developed

TESTING RECOMMENDATIONS FOR SUSPECTED ME/CFS US ME/CFS Clinician Coalition

there are multiple ME severity scales, and exact definitions of what constitutes mild/moderate/severe/very severe vary a bit, but here is one: M.E. Disability Scale, another one is the ME/CFS Disability Rating Scale from ME Association, however the pdf on their website costs so i also have a pdf that i made with the text

pathology:

Brainstem volume changes in myalgic encephalomyelitis/chronic fatigue syndrome and long COVID patients

Decreased oxygen extraction during cardiopulmonary exercise test in patients with chronic fatigue syndrome

Developing a blood cell-based diagnostic test for myalgic encephalomyelitis/chronic fatigue syndrome using peripheral blood mononuclear cells

Human Herpesvirus-6 Reactivation, Mitochondrial Fragmentation, and the Coordination of Antiviral and Metabolic Phenotypes in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

Mitochondrial complex activity in permeabilised cells of chronic fatigue syndrome patients using two cell types

Muscle sodium content in patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

Redox imbalance links COVID-19 and myalgic encephalomyelitis/chronic fatigue syndrome

The use of oxygen as a possible screening biomarker for the diagnosis of chronic fatigue

Tissue specific signature of HHV-6 infection in ME/CFS

treatment (both helpful and harmful):

ME/CFS TREATMENT RECOMMENDATIONS US ME/CFS Clinician Coalition

Low-dose naltrexone in the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/ CFS)

Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment

Back to the Future? Immunoglobulin Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

Evidence Against Exercise for people with PEM/PESE in Long COVID and ME/CFS

PACE trial claims for recovery in myalgic encephalomyelitis/chronic fatigue syndrome – true or false? It’s time for an independent review of the methodology and results

Treatment harms to patients with ME/CFS

[eremitical]

doing some research on the current state of long covid because i'm interested. Below the cut is excerpts from the most comprehensive look at how long covid is doing right now. This was originally going to be a compilation but this article is just the best and it covers a lot of perspectives.

(January 18, 2024)

tl;dr- Long covid rates appear to be going down + recovery from long covid seems to be getting better within cases of more recent infections. Full recovery still remains uncommon+people are less likely to recognize their symptoms as being long covid, so anecdotal evidence of lower long covid rates are somewhat mute. Research results vary as to what preventative measures can result in what efficacy. More recent long covid cases are more likely to experience neurological symptoms than the initial waves of long covid patients.

"Most of the experts I spoke with for this story do think that the average SARS-CoV-2 infection is less likely to unfurl into long COVID than it once was."

"Lisa Sanders, an internal-medicine physician who runs a clinic at Yale, told me that more recent cases of long COVID appear to be less debilitating than ones that manifested in 2020. 'People who got the earliest versions definitely got whacked the worst,' she said."

[when vaccinated,] "courses of illness also tend to end more quickly, with less viral buildup, giving the immune system less time or reason to launch a campaign of friendly fire on other tissues, another potential trigger of chronic disease."

"Others have pointed to the possibility that more recent variants of the virus—some of them maybe less likely to penetrate deeply into the lungs or affect certain especially susceptible organs—may be less apt to trigger chronic illness too."

"But consensus on any of these points is lacking—especially on just how much, if at all, these interventions help. Experts are divided even on the effect of vaccines, which have the most evidence to back their protective punch: Some studies find that they trim risk by 15 percent, others up to about 70 percent. Paxlovid, too, has become a point of contention: Although some analyses have shown that taking the antiviral early in infection helps prevent long COVID, others have found no effect at all. Any implication that we’ve tamed long COVID exaggerates how positive the overall picture is. Hannah Davis, one of the leaders of the Patient-Led Research Collaborative, who developed long COVID during the pandemic’s first months, told me that she’s seen how the most optimistic studies get the most attention from the media and the public. With a topic as unwieldy and challenging to understand as this, Davis said, 'we still see overreactions to good news, and underreactions to bad news.'"

"With vaccines, for instance, the more wide-ranging the set of potential long-COVID symptoms a study looks at, the less effective shots may appear—simply because 'vaccines don’t work on everything,' Al-Aly told me."

"Long COVID remains one of the most debilitating chronic conditions in today’s world—and full recovery remains uncommon, especially, it seems, for those who have been dealing with the disease for the longest." (article linked here is from 2022)

"[Hannah] Davis also worries that recovery rates could drop. Some researchers and clinicians have noticed that today’s new long-COVID patients are more likely than earlier patients to come in with certain neurological symptoms—among them, brain fog and dizziness—that have been linked to slower recovery trajectories, Lekshmi Santhosh, a pulmonary specialist at UCSF, told me."

"Long COVID can also manifest after repeat infections of SARS-CoV-2—and although several experts told me they think that each subsequent exposure poses less incremental risk, any additional exposure is worrisome."

"Even if rates of new long-COVID cases continue to drop for some time, Yonts pointed out, they will likely stabilize somewhere."

[macflorendo]

THANK YOU to life!

This is my Eulogy.

First. I would like to thank Life and God for giving me the opportunity to live and experience a taste of this world.

TO MY FAMILY. Thank you for raising me well. I am not me without any single of you. I may not express as much as needed but I want you to know that I LOVE YOU. See you soon!

I may not be the best son, not the best brother. I don’t wish to be one but I would like to believe that we are destined to be the way we are. Well, that’s where I learn from my lessons from anyway - all my mistakes.

TO THE ENVIRONMENT. I am so proud to have joined Cuernos de Negros Mountaineers Club, Inc. of Silliman University for teaching me how to love the environment. Because of that, I was able to travel to 5 countries (USA, Cambodia, Malaysia, Singapore, Thailand) for FREE to attend different environmental programs and its alumni engagements.

Aside from being able to see different parts of the world. I am fortunate to learn that there is a problem that we need to do something about. Our children’s lives are at stake.

-

MUSIC, MAGIC, & MOVING PICTURES. MY PASSIONS. I cannot thank you enough. We have been through the happiest and most difficult times of my life. When there’s no one else to talk to and hang out with, you were there.

You even got me jobs!

-

SOUTH KOREA. You are my second home country. You made me realize that I am part of the world, a global citizen. There is the potential of anyone to make a difference even to another individual in the world. Thank you Silliman University and Hannam University for this opportunity!

I am happy I am able to learn Korean so I could understand you. Now, I am giving back by learning your language too. South Korea is beautiful. I know most of you are tired of the pressure in your country. But please, never forget your passions and purpose. There’s more to the world than getting a “good” job and lots of money.

-

EVENTS.

2011 - Moved to Dumaguete to study in Silliman University, Dumaguete City. I lived in Vernon Hall inside the campus, lived in an apartment for summer class, and then lived with mom and sister until I graduated.

2013 - I was exchange student to Hannam University in Daejeon, South Korea. That was my first time abroad. I took up Korean Language classes, Faith and Film, and Advance VIdeo Production Class. I taught English to students during my free time and that’s where I got my allowance.

2015 - I became an academic fellow on Environmental Issues under Young Southeasts Leaders Initiative. We went to Hawaii, Colorado, and Washington DC.

- I founded Food Rescue Philippines (formerly Food Rescue ASEAN)

2016 - I graduated Cum Laude from Silliman University.

March 2020. There’s an ongoing virus called COVID-19 infecting people around the world. Who knows what will happen next? We will not be always safe. I live in a dorm, I live with other people. They may be carrying the disease. I hope not. I have one roommate who still goes to work at this time. I hope he won’t bring the disease in the dorm. There’s currently 187 infected patients in the Philippines and recovery rate has not moved at all.

July 2020.  COVID cases are not easing down here in the Philippines. I heard stories of the government just making money out of this situation…

2021 - 2022. Met the worst person in my life. But thank you for making me wiser and way better.

MARCH 2023 - I got hired as Food Rescue Supervisor at Scholars of Sustenance. This is a dream come true. I used to bike and work with volunteers for this advocacy but I now work with a bigger organization that can create more impact.

JULY 2023. I will be turning 30 in 2025. I want to focus on meaningful and valuable work. I also want to create opportunities for myself and others to grow financially, and spriritually.

- 

I am happy that I have experienced many jobs. I realized that I can do so much more, and at the same time, I know I will have options when any career I would choose won’t work.

-

LOVE. Love is a BURST of emotions that happen in your body. That feeling is temporary. When choosing a partner, remember BURST.

B - Believe in each other.

U - Understand each other.

R - Respect each other.

S - Support each other.

T - Trust Each Other

-

MEANING OF MEANING

Meaning starts with ME. Everything you do should start and would meaning something to you.

MEAN has three meanings.

1. what do you mean to say

2. you are so mean

3. what does it mean

MEANING is present tense. Is it something that you currently do. It should be something that you are doing now.

-

A MESSAGE TO MY YOUNGER SELF/TO MY CHILDREN/ TO YOUNG PEOPLE:

1. Exercise more. Play more.

2. Get long hair and donate.

3. Grow a beard! (DONE)

4. Talk to more people. (ALWAYS)

5. Go to more places. Be more adventurous. (BE MORE SPECIFIC)

-

A MESSAGE TO MY FUTURE SELF:

1. Hope you are still doing what you love; performing really good magic, doing something for the environment, helping people, and sharing what you know.

2. Stay fit.

3. Be financially secure.

4. Always learn.

5. Network more. Meet more people.

6. Don’t work for a boring company with boring people.

-

TRAVELS

Countries I traveled to..

2013 - South Korea - Seoul, Daejeon, Busan, Chuncheon, Okcheon, Jeonju

2015 -  USA - Hawaii, Colorado, Washington DC

2015 - Singapore

2015 - Malaysia, Kuala Lumpur

2016 - Thailand, Bangkok

2016 - Cambodia, Siem Reap

2017 - South Korea - Seoul, Daejeon, Pohang, Busan

2020 - Japan - Osaka, Nagoya

2022 - France - Paris

2023 - Thailand - Bangkok

PHILIPPINES

1. Zamboanga

2. Dumaguete

3. Manila

4. Cebu

5. Davao

6. Iloilo

7. Palawan - Puerto Princesa

8. Baguio

9. Tagaytay

10. Bohol

11. Siquijor

12. La Union

13. Zambales

14. Dapitan

15. Bacolod

16. Boracay

17. La Union

18. Pampanga

19. Bulacan

To be continued…

Edited 5/9/2019

Edited 10/2/2019

Edited 3/18/2020

Edited 3/29/2020

Edited 7/23/2020

Edited 9/6/2021

Edited 1/1/2022

Edited 4/14/2022

Edited 7/11/2022

Edited 7/1/2023

[latestmarketresearchnews]

Urinary Catheters Industry Insights and Trends Report by 2030

The global urinary catheters market was valued at USD 5.2 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 5.4% from 2023 to 2030. This growth is driven by a rising number of patients affected by urinary tract infections (UTIs), urethral blockages, tumors in the urinary tract or reproductive organs, and a rapidly increasing elderly population. Urinary catheters are flexible tubes used to drain urine from the bladder, essential for patients who suffer from urinary incontinence, urinary retention, prostate surgery recovery, or other conditions, including spinal cord injuries, multiple sclerosis, or dementia. These catheters are made from materials such as plastic, rubber, and silicon, chosen for their durability and flexibility.

The COVID-19 pandemic has had a notable impact on the demand for urinary catheters. During the pandemic, the use of both urinary catheters and central lines increased as hospitals focused on maintaining infection control and managing patient care for critically ill patients. According to the National Center for Biotechnology Information, the Standardized Utilization Ratio (SUR) of urinary catheters rose by 7.4%, from 0.79 pre-pandemic to 0.84 during the pandemic. This increased utilization is expected to contribute to market growth. Furthermore, the pandemic highlighted the importance of infection prevention, driving manufacturers to develop enhanced products, such as coated urinary catheters with built-in temperature monitoring, aimed at reducing secondary infections in ICU patients. For instance, in February 2021, Health Canada approved Bactiguard’s urine catheter with a temperature sensor for infection prevention, fast-tracking the approval due to COVID-19’s impact on infection rates among ICU patients.

Gather more insights about the market drivers, restrains and growth of the Urinary Catheters Market

Additionally, the pandemic has accelerated the adoption of teleconsultation services for patients with urological conditions, supported by government initiatives in various countries to reduce the risk of COVID-19 transmission. This shift to virtual healthcare has allowed patients to receive consultations without visiting hospitals, further expanding the market. Companies are also launching platforms to provide remote counseling and guidance for patients unable to access in-person care. For example, Nobel Hygiene, an adult diaper brand in India, launched an awareness campaign during lockdowns to help families identify symptoms of urinary incontinence, offering telemedicine support for managing the condition. Such campaigns highlight the rising need for urinary catheters and related products, particularly for elderly patients who suffer from urinary incontinence, thereby boosting market demand over the forecast period.

Application Segmentation Insights:

The Urinary Incontinence (UI) segment was the largest market segment in 2022, capturing over 37.1% of revenue share. Urinary incontinence is prevalent globally, affecting one-third of the population, with a higher incidence in women. This condition is a significant concern for long-term care facilities, as it frequently leads to the admission of elderly individuals into institutional care settings. Factors such as age-related changes in the urinary tract, UTIs, and other health conditions like diabetes, stroke, cancer, and mobility impairments contribute to bladder incontinence. Women, in particular, are more likely to experience stress and urge incontinence. According to the Urology Care Foundation, overactive bladder affects approximately 33 million people in the U.S., with a substantial portion of men and women experiencing UI.

The Benign Prostate Hyperplasia (BPH) and prostate surgeries segment is expected to experience the fastest growth during the forecast period. BPH, also known as an enlarged prostate, is a common condition in men aged 50 and older, leading to uncomfortable urinary symptoms and blockage of urine flow. Treatment for BPH often involves minimally invasive surgeries, which help relieve urinary retention caused by the condition. The increase in awareness about BPH and its impact on patients’ quality of life is contributing to this segment's growth. In addition, statistics from the National Spinal Cord Injury Statistical Center show that approximately 294,000 individuals in the U.S. live with spinal cord injuries, with around 17,810 new cases diagnosed annually. These injuries frequently lead to urinary complications, further driving the need for urinary catheters within this segment.

Overall, the market for urinary catheters is on a steady growth trajectory, driven by the increasing prevalence of urinary conditions, advances in telemedicine, and the critical role of these devices in infection prevention. With ongoing developments in catheter technology and rising awareness of conditions like UI and BPH, the market is poised for continued expansion, particularly in segments related to elderly care and chronic urinary issues.

Order a free sample PDF of the Urinary Catheters Market Intelligence Study, published by Grand View Research.

[researchreportinsight]

Urinary Catheters Industry Growth Analysis, Trends Forecast by Regions and Types to 2030

The global urinary catheters market was valued at USD 5.2 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 5.4% from 2023 to 2030. This growth is driven by a rising number of patients affected by urinary tract infections (UTIs), urethral blockages, tumors in the urinary tract or reproductive organs, and a rapidly increasing elderly population. Urinary catheters are flexible tubes used to drain urine from the bladder, essential for patients who suffer from urinary incontinence, urinary retention, prostate surgery recovery, or other conditions, including spinal cord injuries, multiple sclerosis, or dementia. These catheters are made from materials such as plastic, rubber, and silicon, chosen for their durability and flexibility.

The COVID-19 pandemic has had a notable impact on the demand for urinary catheters. During the pandemic, the use of both urinary catheters and central lines increased as hospitals focused on maintaining infection control and managing patient care for critically ill patients. According to the National Center for Biotechnology Information, the Standardized Utilization Ratio (SUR) of urinary catheters rose by 7.4%, from 0.79 pre-pandemic to 0.84 during the pandemic. This increased utilization is expected to contribute to market growth. Furthermore, the pandemic highlighted the importance of infection prevention, driving manufacturers to develop enhanced products, such as coated urinary catheters with built-in temperature monitoring, aimed at reducing secondary infections in ICU patients. For instance, in February 2021, Health Canada approved Bactiguard’s urine catheter with a temperature sensor for infection prevention, fast-tracking the approval due to COVID-19’s impact on infection rates among ICU patients.

Gather more insights about the market drivers, restrains and growth of the Urinary Catheters Market

Additionally, the pandemic has accelerated the adoption of teleconsultation services for patients with urological conditions, supported by government initiatives in various countries to reduce the risk of COVID-19 transmission. This shift to virtual healthcare has allowed patients to receive consultations without visiting hospitals, further expanding the market. Companies are also launching platforms to provide remote counseling and guidance for patients unable to access in-person care. For example, Nobel Hygiene, an adult diaper brand in India, launched an awareness campaign during lockdowns to help families identify symptoms of urinary incontinence, offering telemedicine support for managing the condition. Such campaigns highlight the rising need for urinary catheters and related products, particularly for elderly patients who suffer from urinary incontinence, thereby boosting market demand over the forecast period.

Application Segmentation Insights:

The Urinary Incontinence (UI) segment was the largest market segment in 2022, capturing over 37.1% of revenue share. Urinary incontinence is prevalent globally, affecting one-third of the population, with a higher incidence in women. This condition is a significant concern for long-term care facilities, as it frequently leads to the admission of elderly individuals into institutional care settings. Factors such as age-related changes in the urinary tract, UTIs, and other health conditions like diabetes, stroke, cancer, and mobility impairments contribute to bladder incontinence. Women, in particular, are more likely to experience stress and urge incontinence. According to the Urology Care Foundation, overactive bladder affects approximately 33 million people in the U.S., with a substantial portion of men and women experiencing UI.

The Benign Prostate Hyperplasia (BPH) and prostate surgeries segment is expected to experience the fastest growth during the forecast period. BPH, also known as an enlarged prostate, is a common condition in men aged 50 and older, leading to uncomfortable urinary symptoms and blockage of urine flow. Treatment for BPH often involves minimally invasive surgeries, which help relieve urinary retention caused by the condition. The increase in awareness about BPH and its impact on patients’ quality of life is contributing to this segment's growth. In addition, statistics from the National Spinal Cord Injury Statistical Center show that approximately 294,000 individuals in the U.S. live with spinal cord injuries, with around 17,810 new cases diagnosed annually. These injuries frequently lead to urinary complications, further driving the need for urinary catheters within this segment.

Overall, the market for urinary catheters is on a steady growth trajectory, driven by the increasing prevalence of urinary conditions, advances in telemedicine, and the critical role of these devices in infection prevention. With ongoing developments in catheter technology and rising awareness of conditions like UI and BPH, the market is poised for continued expansion, particularly in segments related to elderly care and chronic urinary issues.

Order a free sample PDF of the Urinary Catheters Market Intelligence Study, published by Grand View Research.

[industrynewsupdates]

Key Drivers Behind the Growth of the Infection Control Market

The global infection control market was valued at USD 214.0 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 6.7% from 2023 to 2030. This growth is primarily driven by the increasing number of surgical and clinical procedures that require intensive infection prevention measures. The growing preference for infection control products and practices can largely be attributed to the positive clinical outcomes associated with their use in reducing infections. The COVID-19 pandemic further contributed to this market expansion, as the demand for sterilization, disinfection, and infection control solutions surged across hospitals, clinics, and other healthcare facilities, as well as pharmaceutical and medical device companies.

According to statistics from the World Health Organization (WHO), Acute Respiratory Diseases (ARDs) are a leading cause of mortality worldwide, with approximately 4 million deaths occurring each year due to ARDs. This data highlights the pressing need for effective infection control measures globally. Hospital-acquired infections (HAIs) represent another significant area of concern, as they are responsible for a substantial number of patient illnesses and deaths. Common types of HAIs include pneumonia, bloodstream infections, urinary tract infections (UTIs), surgical site infections (SSIs), and Methicillin-resistant Staphylococcus aureus (MRSA). HAIs, such as catheter-associated urinary tract infections, ventilator-associated pneumonia, and catheter-related bloodstream infections, pose major challenges to patient recovery and significantly impact mortality rates worldwide. The high prevalence of HAIs underscores the critical demand for infection control solutions that can improve patient outcomes and reduce the incidence of infections.

Gather more insights about the market drivers, restrains and growth of the Infection Control Market

End-use Insights

The global infection control market is segmented based on end-use into medical device companies, hospitals, pharmaceutical companies, clinical laboratories, and others. The hospital segment accounted for the largest share of the market, holding around 40% of the total revenue in 2022. This segment is expected to continue growing at the fastest rate, with a CAGR of 7.4% from 2023 to 2030. The large market share of hospitals is primarily due to the high risk of infection in hospital settings, where blood-borne, respiratory, and other pathogens can easily spread. Hospital-acquired infections (HAIs) represent a major challenge within these environments, contributing to the need for stringent infection control measures. Research published by the National Center for Biotechnology Information (NCBI) estimates that 40% to 60% of hospital infections are surgical site infections (SSIs), further emphasizing the importance of infection control in surgical settings.

Hospitals are particularly vulnerable to the spread of drug-resistant pathogens, blood-borne pathogens, and other infectious agents in areas such as operating rooms, patient care units, and intensive care units (ICUs). One specific concern is the frequent use of urinary catheters, which are associated with a high risk of urinary tract infections (UTIs), particularly catheter-associated urinary tract infections (CA-UTIs). According to data from the NCBI, UTIs account for approximately 25% of all bacterial infections. Additionally, the National Nosocomial Infection Surveillance (NNIS) system report reveals that catheter-associated bacteriuria and catheterization-related infections are among the most common HAIs in the U.S., contributing to 40% of all HAIs annually.

These alarming statistics highlight the pressing need for infection control measures in hospital settings, especially concerning the prevention of catheter-associated infections and other types of hospital-acquired infections. The high prevalence of these infections, combined with the increasing adoption of advanced infection control technologies, is expected to drive significant market growth in the hospital sector.

The increasing adoption of effective infection control practices in hospitals is therefore expected to boost market demand for products such as sterilization equipment, disinfection solutions, personal protective equipment (PPE), and infection monitoring systems. As the healthcare sector continues to focus on improving patient safety and reducing the burden of HAIs, hospitals will play a crucial role in the overall growth of the infection control market.

Order a free sample PDF of the Infection Control Market Intelligence Study, published by Grand View Research.

[marketanalysisdata]

Sinus Dilation Devices Industry Demand, Trend & Top Key Players Update By 2030

The global market for sinus dilation devices was valued at USD 2.74 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 9.6% from 2023 to 2030. This growth is largely driven by several key factors, including a preference for minimally invasive procedures, improved reimbursement scenarios, rising awareness of the benefits of balloon sinuplasty compared to conventional methods, and the increasing prevalence of chronic sinusitis. Advanced surgical techniques are being developed to replace traditional procedures, further enhancing market dynamics.

Technological advancements, particularly in surgical laser technologies for sinus surgery, have made procedures less invasive with minimal tissue ablation and fewer side effects. These technologies have also reduced the turnaround time, allowing the procedures to be performed in outpatient departments. For instance, in 2022, the National Health Service (NHS) introduced a groundbreaking laser treatment for epilepsy patients, using lasers to precisely target areas of the brain responsible for seizures, illustrating the broader application of laser technology in medical treatments. Although this example pertains to epilepsy, it highlights the role of lasers in providing advanced, minimally invasive medical solutions.

The COVID-19 pandemic disrupted routine healthcare services, including the treatment of sinus-related conditions. Healthcare providers canceled routine visits and elective surgeries to prioritize intensive care and inpatient beds for COVID-19 patients. As a result, patients with chronic sinusitis and other sinus conditions sought teleconsultations and temporary treatments for managing their symptoms during this period.

Gather more insights about the market drivers, restrains and growth of the Sinus Dilation Devices Market

Product Segmentation Insights:

In 2022, the Balloon Sinus Dilation (BSD) devices segment captured the largest share of the market, accounting for over 45% of the revenue. BSD devices are small, flexible, and highly effective at improving sinusitis symptoms, without the need for tissue ablation, which contributes to quick recovery and greater patient comfort. However, since BSD procedures are temporary, patients may require repeat treatments. Balloon sinuplasty is commonly used to treat chronic rhinosinusitis (CRS), a long-term inflammation of the sinuses.

According to the National Center for Biotechnology Information (NCBI), chronic rhinosinusitis (CRS) is a widespread chronic condition affecting individuals across all age groups. The global prevalence of CRS was reported at 12.3% in the U.S., 10.9% in Europe, and 13% in China in 2020. This condition significantly impacts patients' quality of life, even more so than serious health conditions like ischemic heart disease or chronic heart failure.

The Functional Endoscopic Sinus Surgery (FESS) Instruments Set segment is expected to register the fastest growth rate, exceeding 12.5% during the forecast period. FESS is a minimally invasive technique used to treat recurrent acute rhinosinusitis and medically refractory chronic rhinosinusitis (with or without polyps). This procedure's minimal invasiveness and effectiveness have made it highly preferred, fueling the segment’s growth.

According to the Sinus & Allergy Wellness Center of North Scottsdale, sinusitis, which causes inflammation of the sinuses, can develop as a complication in about 0.5% of upper respiratory infections. An estimated 11.6% of American adults are diagnosed with sinusitis each year, resulting in 73 million restricted activity days and a socioeconomic burden of more than USD 5.8 billion annually. Approximately 47% of sinusitis cases resolve within a week without the use of antibiotics, yet the condition still leads to more than 1.3 million hospital visits annually. While treatments like nasal saline can promote quicker recovery, chronic rhinosinusitis often requires long-term treatments, and the use of antibiotics to treat it costs over USD 150 million per year. Given the significant health and economic impact of sinusitis, there is a growing need for more efficient and cost-effective treatments to reduce the burden on patients and healthcare systems.

In conclusion, the sinus dilation devices market is expected to witness strong growth in the coming years due to technological advancements in minimally invasive procedures, rising awareness of the benefits of newer treatment options like balloon sinuplasty, and the increasing prevalence of chronic sinusitis globally. The market's trajectory is further supported by developments in advanced surgical techniques and the growing demand for more effective sinus treatments to address both the medical and economic challenges posed by sinusitis.

Order a free sample PDF of the Sinus Dilation Devices Market Intelligence Study, published by Grand View Research.

[credenceresearchdotblog]

The Prenatal Vitamin Supplement Market is projected to grow from USD 563.41 million in 2023 to an estimated USD 1,126.26 million by 2032, registering a compound annual growth rate (CAGR) of 8.00% from 2024 to 2032.The Prenatal Vitamin Supplement Market is projected to grow from USD 563.41 million in 2023 to an estimated USD 1,126.26 million by 2032, registering a compound annual growth rate (CAGR) of 8.00% from 2024 to 2032.The global respiratory tract infection treatment market has experienced significant growth in recent years due to the rising prevalence of respiratory illnesses, increasing awareness about the importance of early diagnosis and treatment, and the ongoing demand for novel therapeutic options. Respiratory tract infections (RTIs), both upper and lower, remain some of the most common infectious diseases worldwide. They range from mild conditions such as the common cold to more severe diseases like pneumonia, bronchitis, and even life-threatening conditions caused by viruses such as influenza and respiratory syncytial virus (RSV).

Browse the full report at https://www.credenceresearch.com/report/prenatal-vitamin-supplements-market

Market Dynamics

Rising Prevalence of Respiratory Infections One of the major drivers of the market is the increasing incidence of respiratory infections globally. Factors such as growing urbanization, air pollution, and climate change have contributed to the rise in respiratory diseases. Furthermore, the global COVID-19 pandemic has increased awareness about the seriousness of respiratory infections, thus driving the demand for preventive measures, diagnostics, and treatments.

According to the World Health Organization (WHO), lower respiratory tract infections like pneumonia remain a leading cause of mortality in both children and adults worldwide. This has emphasized the need for effective treatment options and boosted investment in research and development for innovative therapies.

Advancements in Treatment Modalities The market for respiratory tract infection treatment has seen significant advancements in both pharmacological and non-pharmacological interventions. Antiviral drugs, antibiotics, and immunotherapies are widely used to treat various respiratory infections. Newer treatment modalities, such as monoclonal antibodies and vaccines targeting specific respiratory pathogens, have expanded the scope of therapeutic options available to healthcare providers.

For instance, vaccines against respiratory infections like pneumococcal pneumonia and influenza are essential preventive measures that have become more widespread, especially in high-risk populations. Moreover, with the rise of antibiotic resistance, there has been a growing focus on developing new classes of antibiotics and alternative therapies, such as bacteriophage therapy and host-directed therapies.

Increasing Research & Development Activities Pharmaceutical companies and research institutions are investing heavily in the development of novel therapies and drugs to treat respiratory infections. The growing focus on personalized medicine, precision diagnostics, and targeted therapies is expected to further enhance treatment outcomes. Additionally, the development of combination therapies that target multiple aspects of the infection process (e.g., viral replication and immune response) has shown promise in improving patient recovery.

A key trend in research is the use of advanced biotechnological approaches to create therapies that can modulate the immune response to respiratory pathogens, rather than simply targeting the pathogens themselves. This approach is especially important for conditions like severe influenza and COVID-19, where an overactive immune response can lead to complications such as acute respiratory distress syndrome (ARDS).

Market Challenges

Antibiotic Resistance One of the major challenges facing the respiratory tract infection treatment market is the increasing rate of antimicrobial resistance (AMR). Overuse and misuse of antibiotics have led to the emergence of resistant strains of bacteria, making it difficult to treat infections effectively. This has prompted a significant need for new antibiotics and alternative treatments. Pharmaceutical companies face the dual challenge of developing novel antibiotics while ensuring their responsible use to prevent further resistance.

High Treatment Costs The cost of treatment, especially for more severe infections requiring hospitalization, can be prohibitive for many patients, particularly in low- and middle-income countries. While the availability of generic drugs helps to reduce costs, advanced therapies like biologics and monoclonal antibodies can be expensive, limiting access for many patients.

Regulatory Hurdles Regulatory approval for new drugs and therapies remains a lengthy and expensive process. Stringent regulations and the need for extensive clinical trials to demonstrate safety and efficacy can delay the introduction of new treatments to the market. Additionally, the varying regulatory frameworks across different regions can create obstacles for companies aiming to launch their products globally.

Future Outlook and Opportunities

The respiratory tract infection treatment market is expected to continue its upward trajectory, driven by several factors. The growing geriatric population, who are more susceptible to respiratory infections, will contribute to increased demand for treatment options. Additionally, the ongoing development of vaccines and antiviral therapies for emerging viral pathogens like SARS-CoV-2 and RSV is likely to further boost market growth.

Telemedicine and digital health solutions are emerging as promising tools in the management of respiratory infections, offering remote consultation and monitoring, particularly in rural or underserved areas. Moreover, partnerships between pharmaceutical companies and academic institutions are expected to accelerate the discovery of novel treatments and diagnostics.

Segments

Based on product

Capsules/Tablets

Powder

Gummy

Liquid

Others

Based on nature

Organic

Conventional

Based on distribution channel

Supermarkets & Hypermarkets

Pharmacy & Drug Stores

Online

Others

Based on region

North America

U.S.

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

South-east Asia

Rest of Asia Pacific

Latin America

Brazil

Argentina

Rest of Latin America

Middle East & Africa

GCC Countries

South Africa

Rest of the Middle East and Africa

Browse the full report at https://www.credenceresearch.com/report/prenatal-vitamin-supplements-market

About Us:

Credence Research is committed to employee well-being and productivity. Following the COVID-19 pandemic, we have implemented a permanent work-from-home policy for all employees.

Contact:

Credence Research

Please contact us at +91 6232 49 3207

Email: sales@credenceresearch.com

Website: www.credenceresearch.com

[covid-safer-hotties]

Reference archived on our website

Highlights • Long-COVID is heterogeneous in its symptoms, severity, and illness duration. • There was no association between long-COVID and cognitive performance. • Cognitive symptoms may represent functional cognitive disorders. • Long-COVID had lower mean diffusivity on diffusion imaging than normal recovery. • Diffusion imaging differences may suggest gliosis as a mechanism of long-COVID.

To be clear: There was no cognitive difference between people post infection. I can see some people misunderstanding what this says. It says there is some form of brain damage from covid across the board, even if you don't have long covid symptoms or diagnosis.

Abstract

Background

The pathophysiology of protracted symptoms after COVID-19 is unclear. This study aimed to determine if long-COVID is associated with differences in baseline characteristics, markers of white matter diffusivity in the brain, and lower scores on objective cognitive testing.

Methods

Individuals who experienced COVID-19 symptoms for more than 60 days post-infection (long-COVID) (n = 56) were compared to individuals who recovered from COVID-19 within 60 days of infection (normal recovery) (n = 35). Information regarding physical and mental health, and COVID-19 illness was collected. The National Institute of Health Toolbox Cognition Battery was administered. Participants underwent magnetic resonance imaging (MRI) with diffusion tensor imaging (DTI). Tract-based spatial statistics were used to perform a whole-brain voxel-wise analysis on standard DTI metrics (fractional anisotropy, axial diffusivity, mean diffusivity, radial diffusivity), controlling for age and sex. NIH Toolbox Age-Adjusted Fluid Cognition Scores were used to compare long-COVID and normal recovery groups, covarying for Age-Adjusted Crystallized Cognition Scores and years of education. False discovery rate correction was applied for multiple comparisons.

Results

There were no significant differences in age, sex, or history of neurovascular risk factors between the groups. The long-COVID group had significantly (p < 0.05) lower mean diffusivity than the normal recovery group across multiple white matter regions, including the internal capsule, anterior and superior corona radiata, corpus callosum, superior fronto-occiptal fasciculus, and posterior thalamic radiation. However, the effect sizes of these differences were small (all <|0.3|) and no significant differences were found for the other DTI metrics. Fluid cognition composite scores did not differ significantly between the long-COVID and normal recovery groups (p > 0.05).

Conclusions

Differences in diffusivity between long-COVID and normal recovery groups were found on only one DTI metric. This could represent subtle areas of pathology such as gliosis or edema, but the small effect sizes and non-specific nature of the diffusion indices make pathological inference difficult. Although long-COVID patients reported many neuropsychiatric symptoms, significant differences in objective cognitive performance were not found.

[medlama]

Tocilizumab: An Essential Medication for Managing Autoimmune Disorders

Tocilizumab, also known by its brand name ACTEMRA INJECTION, has become an essential treatment for various inflammatory conditions, including rheumatoid arthritis (RA), juvenile idiopathic arthritis, and cytokine release syndrome (CRS). More recently, it has played a critical role in managing severe cases of COVID-19. But what exactly is Tocilizumab, how does it work, and what should patients know about its uses and price? In this post, we’ll walk you through the key aspects of Tocilizumab, its significance in healthcare, and what to expect if you’re prescribed this medication.

Tocilizumab: An Overview

Tocilizumab is a monoclonal antibody that targets the IL-6 receptor, which is involved in the body’s immune response. IL-6 is a protein that can cause inflammation, particularly in autoimmune diseases where the immune system mistakenly attacks healthy cells. By inhibiting the IL-6 receptor, Tocilizumab helps reduce inflammation and prevent damage to tissues and organs.

Initially developed for autoimmune disorders like RA, Tocilizumab’s scope has broadened, especially during the COVID-19 pandemic. It is typically administered as an intravenous (IV) infusion or subcutaneous injection, depending on the condition being treated.

Tocilizumab – Uses & Introduction

Tocilizumab is a versatile drug with multiple applications. It is commonly prescribed for autoimmune diseases like rheumatoid arthritis and juvenile idiopathic arthritis, providing relief from debilitating joint pain, swelling, and other symptoms caused by chronic inflammation.

In addition, Tocilizumab is approved for treating cytokine release syndrome (CRS), a severe side effect of cancer therapies like CAR T-cell therapy, where the immune system releases excessive cytokines, leading to dangerous inflammation. In such cases, Tocilizumab helps control this immune overreaction and prevents life-threatening complications.

More recently, Tocilizumab has gained recognition for its effectiveness in treating severe COVID-19 cases, particularly in patients experiencing acute respiratory distress. By reducing the immune system’s overreaction to the virus, Tocilizumab offers critically ill patients a better chance of recovery.

How Does Tocilizumab Work?

Tocilizumab works by targeting and blocking the IL-6 receptor, a protein that plays a critical role in immune regulation. While IL-6 is necessary for normal immune function, excessive IL-6 levels can trigger harmful inflammation, especially in autoimmune diseases and severe infections like COVID-19.

When administered, Tocilizumab binds to the IL-6 receptor and prevents it from signaling the immune system to produce more inflammation. This reduces symptoms such as pain, swelling, and fever, bringing balance to the immune response while still allowing the body to fight infections or other threats.

The drug’s impact varies depending on the condition being treated, but many patients experience significant relief, particularly those with RA and CRS. In the context of COVID-19, Tocilizumab has been shown to lower the need for mechanical ventilation and improve survival rates in severely ill patients.

ACTEMRA INJECTION: A Key Brand

ACTEMRA INJECTION, the branded version of Tocilizumab, is available in two forms: intravenous infusion and subcutaneous injection. The choice between these options depends on the patient’s condition and the severity of their symptoms.

For instance, rheumatoid arthritis patients may prefer the subcutaneous injection for its convenience, as it can be administered at home. Conversely, patients with severe COVID-19 or CRS may require IV infusions, which are given in hospital settings.

Although ACTEMRA INJECTION is generally well-tolerated, potential side effects include headaches, high blood pressure, respiratory infections, and injection site reactions. More serious but rare side effects, such as liver damage and gastrointestinal perforations, make it necessary for patients to be closely monitored throughout treatment.

Tocilizumab Injection Price: What to Expect

The Tocilizumab Injection price can vary based on factors such as dosage, form (IV or subcutaneous), and location. Like many biologic drugs, Tocilizumab is not inexpensive, with costs ranging from several hundred to a few thousand dollars per dose, depending on the treatment plan.

Many health insurance plans cover Tocilizumab, especially when prescribed for FDA-approved uses like rheumatoid arthritis or CRS. However, if you’re concerned about out-of-pocket expenses, it’s essential to explore options regarding the Tocilizumab Injection price. Medlama can help you explore financial assistance programs that may reduce the cost of treatment. Talking to a healthcare or pharmacy counselor can help you secure the best possible offer, ensuring access to this vital medication without significant financial strain.

Side Effects and Monitoring During Treatment

While Tocilizumab is effective and generally safe, patients should be aware of potential side effects. Common side effects include:

Upper respiratory infections like colds and sinus infections

Headaches and dizziness

Injection site reactions such as redness, swelling, or pain

Elevated liver enzymes, which may signal liver stress

More serious but rare side effects include gastrointestinal perforations and severe allergic reactions. Tocilizumab can also weaken the immune system, increasing the risk of infections. Therefore, it’s essential for patients to be closely monitored, particularly those on long-term treatment for conditions like RA.

Patients will undergo regular blood tests to ensure proper liver function and monitor for any potential complications. Despite the risks, the overall benefits of Tocilizumab make it a powerful option for patients who haven’t responded to other treatments.

Conclusion: A Vital Drug for Multiple Conditions

Tocilizumab, marketed as ACTEMRA INJECTION, plays a crucial role in managing autoimmune diseases such as rheumatoid arthritis, as well as life-threatening conditions like severe COVID-19 and cytokine release syndrome. By targeting the IL-6 receptor, it reduces inflammation and provides relief for patients suffering from chronic immune conditions.

While the Tocilizumab Injection price can be high, many patients find the benefits outweigh the cost, especially when financial assistance programs are available. If you or a loved one has been prescribed Tocilizumab, it’s essential to understand the medical and financial aspects of this treatment. For personalized support and assistance in navigating treatment costs, talk to your healthcare provider or pharmacy counselor at Medlama, who can help explore the best options for managing your care.

[anertep1]

New Technologies in Healthcare & Health Information Technology Services

The healthcare industry is experiencing a technological revolution, with innovations poised to transform patient care and streamline operations. These advancements are creating a more efficient, effective, and patient-centered healthcare system. From artificial intelligence (AI) to telemedicine, New Technologies in Healthcare are reshaping healthcare delivery, improving outcomes, and reducing costs.

Artificial Intelligence and Machine Learning

Artificial intelligence (AI) and machine learning (ML) are at the forefront of healthcare innovation. AI algorithms can analyze vast amounts of data to identify patterns and predict outcomes, enabling early diagnosis and personalized treatment plans. For instance, AI-powered diagnostic tools can detect diseases like cancer at their earliest stages, improving survival rates. Machine learning models can also predict patient deterioration, allowing for timely interventions and better management of chronic diseases.

Telemedicine and Remote Monitoring

Telemedicine has seen unprecedented growth, especially in the wake of the COVID-19 pandemic. This technology allows patients to consult with healthcare providers from the comfort of their homes, reducing the need for in-person visits and minimizing the risk of infection. Remote monitoring devices, such as wearable health trackers, enable continuous health monitoring, providing real-time data to healthcare professionals. This continuous flow of information allows for proactive management of conditions and can lead to more personalized care.

Electronic Health Records (EHRs) and Health Information Exchanges (HIEs)

Electronic health records (EHRs) have replaced paper-based systems, providing a centralized and accessible way to store patient information. EHRs improve coordination between different healthcare providers, ensuring that patients receive comprehensive and consistent care. Health Information Exchanges (HIEs) facilitate the secure sharing of Health Information Technology Services across different systems and institutions, further enhancing collaboration and reducing duplication of tests and procedures.

Robotics and Automation

Robotic technology is making significant strides in healthcare, particularly in surgery and rehabilitation. Surgical robots offer precision and control that surpasses human capability, leading to minimally invasive procedures, reduced recovery times, and improved outcomes. Automation in administrative tasks, such as appointment scheduling and billing, reduces the burden on healthcare staff and minimizes errors, allowing them to focus more on patient care.

Blockchain Technology

Blockchain technology is emerging as a solution to enhance the security and integrity of health data. Its decentralized nature ensures that patient information is stored securely and is only accessible to authorized individuals. Blockchain can also streamline administrative processes, such as claims processing and supply chain management, by providing a transparent and immutable record of transactions.

 

The integration of new technologies in healthcare and health information technology services is revolutionizing the industry. Companies like Anertep are at the forefront of this transformation, leveraging these innovations to enhance patient care, improve operational efficiency, and ensure the security of health data. As technology continues to advance, the healthcare landscape will become increasingly interconnected and patient-centered, paving the way for a healthier future.

[healthcarehubhh]

Catheters Market to Reach US$54.68 Bn by 2024 Owing to Growing Geriatric Population

The catheters market has witnessed substantial growth owing to increased prevalence of target diseases and growth in the geriatric population who are more prone to chronic diseases requiring long-term treatment. Catheters are medical tubes that can be inserted in the body to treat diseases or perform a surgical procedure. Catheters are increasingly being used in situations like urinary incontinence, cardiovascular diseases, neurovascular diseases, and urological surgeries. Catheters play an important role in medical procedures by enabling drainage, infusion of fluids, access, or pressure monitoring. The Global Catheters Market is estimated to be valued at US$ 54.68 Bn in 2024 and is expected to exhibit a CAGR of 6.4% over the forecast period 2023 to 2030. Key Takeaways Key players operating in the catheters market are Medtronic, ConvaTec, Inc., Smith Medical (Smith Group Plc.), Boston Scientific Corporation, Hollister Incorporated, and Edwards Lifesciences Corporation, among others. These players are focused on leveraging opportunities posed by the epilepsy treatment market through collaborations and partnerships with other players as well as expansion in emerging geographies. The growing geriatric population and their increasing vulnerability to various illnesses has augmented the demand for catheters globally. Advancements in catheter technology and material such as hydrophilic coatings, drugs coated on catheter surfaces to prevent infection and blockages, and safety engineered catheters has improved outcomes for various catheter-based procedures. Market Trends The trend of minimally invasive procedures has gained traction in the catheters market. Catheters are increasingly being used in minimally invasive surgeries as they reduce recovery time, trauma, and risks associated with open surgeries. Catheters are used in catheter-based ablation and angioplasty to treat cardiovascular diseases. Growing adoption of antimicrobial coatings on catheters is another key trend. Catheters coated with antibiotics, silver, or other compounds prevent infections of catheter sites and reduce healthcare costs associated with treatment and extended hospital stays. Market Opportunities Rising disease incidence rates especially of aging-related chronic illnesses in developing countries presents lucrative opportunities. The market players are focusing their efforts on these emerging economies. Growing demand for home healthcare and ambulatory services also creates opportunities for Foley catheters and vascular access catheters that can facilitate long-term treatment at home. Development of bioabsorbable catheters that dissolve and do not require removal post-procedure also has strong prospects. Impact of COVID-19 on Catheters Market Growth The outbreak of the COVID-19 pandemic has negatively impacted the growth of the global catheters market. During the initial lockdown imposed across various countries, all non-essential medical procedures and surgeries were postponed or canceled to focus medical resources on COVID patients. This resulted in a steep decline in the demand for various types of catheters used in surgeries and procedures. Moreover, supply chains were disrupted worldwide due to transportation restrictions imposed during lockdowns. This led to shortages and delays in the supply of raw materials for catheter manufacturing. However, with the lifting of lockdowns in 2021, the demand for catheters started recovering. Certain types of invasive procedures saw increased demand as patients sought them to avoid deterioration in their health conditions. The focus also shifted to developing catheters that aid in COVID treatment. For instance, feeding tubes are being used to supply nutrition to critically ill patients on ventilators.

[industryforecastnews]

Burn Care Centers Market Size To Reach USD 31.9Bn By 2030

Burn Care Centers Market Growth & Trends

The global burn care centers market size is expected to reach USD 31.9 billion by 2030, as per a new report by Grand View Research, Inc. The market is projected to expand at a CAGR of 4.2% from 2023 to 2030. The increasing global caseload is responsible for nearly 180,000 mortalities each year, as per the WHO. The majority of these incidences and accidents occur in lower-middle-income countries in the Asia Pacific and Latin American regions. The current market is witnessing an overall increase in the cost of care, which is a major driver behind the growth of the market.

According to an article published on UpToDate, burns rank 4th in the common types of trauma, on a global level. It also states that low-middle income countries despite having high incidences of trauma, severely lack the necessary infrastructure and means to manage these patients. Another article published in Annals of Burns and Fire Disasters states that treatment and care in most of these countries are often delayed. Rural areas are more severely impacted due to the lack of proper medical facilities. For instance, in Ghana, only 48% of Pediatric injuries are treated at modern healthcare facilities.

In the facility type, the in-hospital type held the largest revenue share of more than 51.1% in 2022. The majority of developing and underdeveloped nations have a scarcity of specialized treatment units, due to which the patient load or volume goes to in-hospital settings. In these countries, the cost of care at specialized treatment units is much higher and is another reason why in-hospital settings record the majority of admissions. However, the stand-alone centers are forecasted to see a surge in growth rate. This can be credited to the growing need for the quality of care and management of patients that these units are capable of delivering.

In the treatment type, the largest revenue share was held by the wound-debridement section. It is the standard procedure in case of all injuries, this not only helps in avoiding infections but also promotes faster healing resulting in better outcomes. The highest growth potential has been exhibited by the pain management section for treatment type. Pain management in patients has come to be of paramount importance even when deciding the kind of wound dressing to be used for the patient. The pain during the healing process can have severe psychological implications due to which the recovery can be hampered, this is a primary driver for growth in this treatment type. A research article published in the Burns journal stated that the patient population studied considered several important factors while considering the type of dressing, nearly 80% responded with pain-free dressings as the most important characteristic.

The partial-thickness burns segment held the largest revenue share in 2022. The majority of the cases fall into the category of less than 10% TBSA. Partial-thickness wounds if not treated timely and properly can fester into infections and can turn fatal. The fastest growth is to be exhibited by the full-thickness burns and require management at specialized medical centers which are capable of providing advanced surgical and non-surgical interventions in care management. The in-patient services segment held the largest revenue share in 2022, owing to the increasing cost of treatment. There has been an overall decline in the annual number of cases, especially during COVID and otherwise as well. Workplaces have fire-safety norms in place to better manage situations to avoid accidents. The cost of care, however, has risen, and thus the market is growing. It is expected to grow lucratively during the forecast period.

North America accounted for the majority revenue share of over 44.1% in 2022. The region has the largest number of specialized burn care units, totaling to 120, across the U.S., many of which are verified by the American Burn Association. The reimbursement plans for patients also significantly support the growth of the North American market. The fastest growth however is being seen in the Asia Pacific region. This can be attributed to the improving healthcare infrastructure due to increased healthcare spending. As per World Bank data, East Asia and Pacific’s annual healthcare spending in 2019 was 6.7% of the region’s GDP, higher than the 2018 value.

The lack of proper resources has also been providing a necessary push to the concerned authorities to bring about the formation of specialized treatment units in the region’s countries. The above-listed reasons are contributing significantly to the growth of the market. There was an overall decline in the number of patients going to burn care units in hospitals or burn centers, the major focus was on the COVID-19 pandemic. However, due to global lockdowns and cross-border trade restrictions, the cost of materials and amenities shot up, ultimately increasing the overall cost of care being delivered to burn patients across the globe.

Request a free sample copy: https://www.grandviewresearch.com/industry-analysis/burn-care-centers-market  

Burn Care Centers Market Report Highlights

The market revenue is expected to reach USD 31.9 billion by 2030. The increasing need to find specialized care for burn patients is driving the market

The in-hospital segment bagged the largest revenue share owing to the limited number of specialized units

The pain management segment is anticipated to emerge as the fastest-growing treatment type for burn patients across the globe

Burn Care Centers Market Segmentation

Grand View Research has segmented the global burn care centers market based on facility type, procedure type, burn severity, service type, and region:

Burn Care Centers Facility Type Outlook (Revenue, USD Million, 2016 - 2030)

In-hospital

Standalone

Burn Care Centers Procedure Type Outlook (Revenue, USD Million, 2016 - 2030)

Wound debridement

Skin graft

Wound management

Respiratory intubation and ventilation

Pain management

Blood transfusion

Infection control

Rehabilitation

Burn Care Centers Burn Severity Outlook (Revenue, USD Million, 2016 - 2030)

Minor Burns

Partial Thickness Burns

Full Thickness Burns

Burn Care Centers Service Type Outlook (Revenue, USD Million, 2016 - 2030)

Inpatient

Outpatient

Rehabilitation

Burn Care Centers Regional Outlook (Revenue, USD Million, 2016 - 2030)

North America

U.S.

Canada

Europe

Germany

U.K.

France

Italy

Spain

Russia

Asia Pacific

Japan

China

India

Australia

South Korea

Latin America

Mexico

Brazil

Argentina  

Middle East & Africa   

South Africa

Saudi Arabia

UAE

List of Key Players in the Burn Care Centers Market

LAC+USC Medical Burn Center

Weill Cornell Medicine William Randolph Hearst Burn Center

Temple University Hospital Adult Burn Center

Parkland Memorial Hospital Regional Burn Center

Medstar Washington Hospital Center

UMC Lions Burn Center

Burn and Reconstructive Centers of America

Pediatric Burn Care Center (The General Hospital Corporation)

University of Rochester Medical Center

Chelsea & Westminster Hospital

St. Barnabas Burn Center

National Burns Center

Browse Full Report: https://www.grandviewresearch.com/industry-analysis/burn-care-centers-market